Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARM NASDAQ:EVGN NASDAQ:INKT NYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARMCarisma Therapeutics$0.35-7.6%$0.33$0.14▼$1.27$14.45M1.828.19 million shs961,125 shsEVGNEvogene$1.24-2.7%$1.28$0.95▼$3.32$6.63M1.16798,909 shs47,857 shsINKTMiNK Therapeutics$14.27-0.9%$16.88$4.56▼$76.00$64.50M0.33373,751 shs28,693 shsVNRXVolitionRx$0.63-3.9%$0.67$0.40▼$0.94$67.81M1.27198,148 shs135,733 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARMCarisma Therapeutics0.00%-6.92%+28.12%-12.94%-63.32%EVGNEvogene0.00%+5.57%-5.93%-16.45%-55.90%INKTMiNK Therapeutics0.00%-2.70%-3.42%+95.65%+85.69%VNRXVolitionRx0.00%+8.99%-5.58%-8.25%-3.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARMCarisma Therapeutics$0.35-7.6%$0.33$0.14▼$1.27$14.45M1.828.19 million shs961,125 shsEVGNEvogene$1.24-2.7%$1.28$0.95▼$3.32$6.63M1.16798,909 shs47,857 shsINKTMiNK Therapeutics$14.27-0.9%$16.88$4.56▼$76.00$64.50M0.33373,751 shs28,693 shsVNRXVolitionRx$0.63-3.9%$0.67$0.40▼$0.94$67.81M1.27198,148 shs135,733 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARMCarisma Therapeutics0.00%-6.92%+28.12%-12.94%-63.32%EVGNEvogene0.00%+5.57%-5.93%-16.45%-55.90%INKTMiNK Therapeutics0.00%-2.70%-3.42%+95.65%+85.69%VNRXVolitionRx0.00%+8.99%-5.58%-8.25%-3.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARMCarisma Therapeutics 2.71Moderate Buy$1.93456.68% UpsideEVGNEvogene 3.50Strong Buy$3.50183.10% UpsideINKTMiNK Therapeutics 2.60Moderate Buy$37.50162.79% UpsideVNRXVolitionRx 3.00Buy$3.50455.38% UpsideCurrent Analyst Ratings BreakdownLatest CARM, EVGN, INKT, and VNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/18/2025INKTMiNK TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$35.00 ➝ $35.008/15/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/11/2025EVGNEvogeneAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025CARMCarisma TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/15/2025CARMCarisma TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.007/11/2025INKTMiNK TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARMCarisma Therapeutics$19.63M0.74N/AN/A($0.67) per share-0.52EVGNEvogene$9.44M0.70N/AN/A$2.77 per share0.45INKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/AVNRXVolitionRx$1.32M51.40N/AN/A($0.11) per share-5.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARMCarisma Therapeutics-$60.48M-$1.56N/AN/AN/A-254.28%N/A-192.17%11/6/2025 (Estimated)EVGNEvogene-$16.49M-$2.25N/A∞N/A-211.61%-109.96%-38.47%11/19/2025 (Estimated)INKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.25N/A∞N/A-2,321.14%N/A-163.39%N/ALatest CARM, EVGN, INKT, and VNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARMCarisma TherapeuticsN/AN/AN/AN/AN/AEVGNEvogeneN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARMCarisma TherapeuticsN/A0.480.48EVGNEvogeneN/A1.891.76INKTMiNK TherapeuticsN/A0.150.15VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARMCarisma Therapeutics44.27%EVGNEvogene10.40%INKTMiNK Therapeutics2.87%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipCARMCarisma Therapeutics6.90%EVGNEvogene7.40%INKTMiNK Therapeutics22.48%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARMCarisma Therapeutics2041.79 million38.91 millionNo DataEVGNEvogene1405.37 million4.97 millionOptionableINKTMiNK Therapeutics304.52 million3.51 millionNo DataVNRXVolitionRx80107.60 million80.80 millionOptionableCARM, EVGN, INKT, and VNRX HeadlinesRecent News About These CompaniesD. Boral Capital Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)September 12 at 8:19 AM | marketbeat.comVolitionRx signs first human out licensing deal for APSSeptember 9, 2025 | msn.comVolition Signs First Human Out Licensing DealSeptember 9, 2025 | prnewswire.comZacks Small Cap Estimates VolitionRx Q3 EarningsAugust 29, 2025 | marketbeat.comQ3 Earnings Forecast for VolitionRx Issued By HC WainwrightAugust 22, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of VolitionRx Q4 EarningsAugust 21, 2025 | marketbeat.comVolitionRx Limited (AMEX:VNRX) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comVolitionRx Limited (VNRX) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comVolitionRx reports Q2 revenue $400K, consensus $375.72KAugust 14, 2025 | msn.comVolitionRx Limited Announces Second Quarter 2025 Financial Results and Business UpdateAugust 14, 2025 | prnewswire.comInsights into VolitionRX's Upcoming EarningsAugust 14, 2025 | benzinga.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...August 8, 2025 | gurufocus.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business UpdateAugust 8, 2025 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in StockAugust 7, 2025 | insidertrades.comVolitionRx Announces Pricing of $1.2 Million Registered Direct OfferingAugust 4, 2025 | prnewswire.comNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16, 2025 | prnewswire.comVolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 11, 2025 | msn.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARM, EVGN, INKT, and VNRX Company DescriptionsCarisma Therapeutics NASDAQ:CARM$0.35 -0.03 (-7.56%) Closing price 04:00 PM EasternExtended Trading$0.34 0.00 (-1.39%) As of 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Evogene NASDAQ:EVGN$1.24 -0.03 (-2.65%) Closing price 03:59 PM EasternExtended Trading$1.26 +0.02 (+1.92%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.MiNK Therapeutics NASDAQ:INKT$14.27 -0.13 (-0.90%) Closing price 04:00 PM EasternExtended Trading$14.22 -0.04 (-0.32%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.VolitionRx NYSE:VNRX$0.63 -0.03 (-3.95%) Closing price 03:59 PM EasternExtended Trading$0.63 0.00 (-0.03%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
